Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.49 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.49 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.30 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.30 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23336222 | 0.83 | CHRNB2 (0.33) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL22355634 | 0.80 | EGFR (0.37) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL20093385 | 0.80 | ALDH1A1 (0.44) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL30154155 | 0.80 | HCAR2 (0.48) | KEAP1NFE2L2HCAR2 | |
| SCHEMBL7928560 | 0.79 | CHRNB2 (0.55) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL20425354 | 0.79 | CHRNB2 (0.55) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL27451892 | 0.79 | CHRNB2 (0.55) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL2836506 | 0.78 | TSHR (0.39) | HCAR2 | |
| SCHEMBL2836509 | 0.78 | TSHR (0.39) | HCAR2 | |
| SCHEMBL22344707 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210315894-A9 | 4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-10-14 | — | — | US | disclosed |
| EP-3057956-B1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA FARBER CANCER INST INC (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20200338075-A1 | 4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-29 | — | — | US | disclosed |
| US-20160264554-A1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. | 2016-09-15 | — | — | US | disclosed |
| WO-2015058140-A1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200338075-A1 | 4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF | CDK3, CDK1, CDK14 | CHRNB2 4086/4885CHRNA4 3197/4885CHRNB4 3402/4885 |
| US-20210315894-A9 | 4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF | CDK3, CDK1, CDK14 | CHRNB2 4086/4885CHRNA4 3197/4885CHRNB4 3402/4885 |
| US-20160264554-A1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK13, CDK3, CDK12 | CHRNB2 4305/4885CHRNA4 4329/4885CHRNB4 4361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.